Recursion Q1 net loss widens to $202.5M; Sanofi milestone $7M; pipeline refocused

RECURSION PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$0.50 revenue$14,745,000

Q1 net loss $202.5M vs $91.4M YoY; revenue $15M (up from $14M).
Cash & equivalents $509M; projected cash runway into mid-2027; 2025 cash burn ≤$450M.
Achieved 4th Sanofi milestone, $7M payment; total Sanofi cash inflow $130M to date.
Deprioritized 3 clinical programs (REC-2282, REC-994, REC-3964) to focus on oncology and rare disease.
REC-4881 preliminary data: median 43% polyp burden reduction in FAP Phase 1b/2 study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.